- Poster presentation
- Open Access
Efficacy and safety of methotrexate treatment of juvenile localized scleroderma
Pediatric Rheumatology volume 6, Article number: P230 (2008)
Our goal is to study the efficacy and safety of MTX in juvenile localized scleroderma (JLS).
Retrospective study of 59 chlidren with JLS from 3 to 17 y (M = 10.3) treated with MTX was performed. Group 1 (n = 18) – received prednisone 0.5 mg\kg for 6 weeks, taped to 0.1 mg\kg for 12 months + MTX 10 mg\body sq. weekly for 13.7 mo. Group 2 (n = 41) -MTX the same doses and duration. The efficacy was measured in 6 & 12 months using skin score, activity and sclerosis indexes (IA, IS) (1 – 3 points) of skin damage, the safety by clinical & laboratory methods. Group 1 patients had spread linear skin involvement (hemitype), with skin score significantly higher (p < 0.01) than in group 2, where children had mostly local linear skin damage. Previously 9 pts from Group 1, 31 pts from Group 2 received penicillamine (PA) with no effect.
MTX therapy was effective in 73% of children unsuccessfully treated with PA & in 98% of patients received MTX as the first medication. Effect of therapy was significantly better in pts with disease duration less than 6 mo. In Group 1 significant improvement (p < 0.01) in skin score, IA, IS had been already achieved in 6 months of treatment, in Group 2 only in 12 mo. MTX was effective in children with linear skin, periarticular contractures. Nausea was the main adverse effect, in 17% of pts, with no correlation with genetic polymorfisms of methylenetetrahydrofolate reductase.
MTX is effective and safe in linear JLS.
Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI: Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006, 155 (5): 1013-1020. 10.1111/j.1365-2133.2006.07497.x.
About this article
Cite this article
Osminina, M., Geppe, N., Tougarinova, G. et al. Efficacy and safety of methotrexate treatment of juvenile localized scleroderma. Pediatr Rheumatol 6, P230 (2008). https://doi.org/10.1186/1546-0096-6-S1-P230
- Public Health
- Adverse Effect
- Retrospective Study